Skip to main content

Table 1 Baseline characteristics of the study subjects

From: The association of tumor necrosis factor superfamily 13 with recurrence of immunoglobulin A nephropathy in living related kidney transplantation

  All Recurrence Non-recurrence p-value
Patients, n 69 11 58
Age, years 43.7 ± 13.4 43.4 ± 13.5 43.8 ± 13.5 0.923
Sex (male/female) 40/29 10/1 28/30 0.019
Dialysis/Preemptive kidney transplantation 53/16 9/2 44/14 1.000
Living related donor 36 (52.2) 7 (63.6) 29 (50.0) 0.406
Panel reactive activity > 50% 10 (14.5) 0 (0) 10 (17.2) 0.345
Desensitization treatment 13 (18.8) 1 (9.1) 12 (20.7) 0.676
Number of HLA mismatches 2.88 ± 1.84 2.45 ± 1.97 2.97 ± 1.82 0.354
ABO incompatible transplantation 10 (14.5) 1 (9.1) 9 (15.5) 1.000
Induction treatment (ATG/anti-IL-2) 0/68 0/10 0/58 0.159
Mean follow up duration after transplantation (days) 1835 ± 440 1782 ± 542 1845 ± 423 0.663
Time to transplantation from dialysis (days, IQR) 1387 ± 1611
(84–2109)
1514 ± 1477
(219–2516)
1360 ± 1652
(83–2133)
0.568
Acute rejection 32 (46.4) 8 (72.7) 24 (41.4) 0.056
Mean time of recurrence of IgA on allograft (days, IQR) 614 ± 443
(390–726)
Serum creatinine (at time of recurrence, mg/dL)   2.96 ± 1.52   
eGFR-time slope (delta eGFR/year) −3.64 ± 4.88 −4.50 ± 3.99 −3.47 ± 5.04 0.302
HLA-A2 30 (43.5) 6 (54.5) 24 (41.4) 0.514
HLA-B35 12 (17.4) 2 (18.2) 10 (17.2) 1.000
HLA-DR4 40 (58.0) 9 (81.8) 31 (53.4) 0.104
Tacrolimus 66 (95.7) 10 (90.9) 56 (96.6) 0.411
Cyclosporine 7 (10.1) 2 (18.2) 5 (8.6) 0.309
Mycophenolate mofetil 53 (76.8) 7 (63.6) 46 (79.3) 0.265
Trough level of tacrolimus within one year from transplantation 8.30 ± 1.70 8.92 ± 1.38 8.19 ± 1.74 0.218
TNFSF13 (ng/mL) 16.03 ± 12.95 17.75 ± 14.14 15.66 ± 12.79 0.525
Gd-IgA1 (units/ng IgA) 5.77 ± 6.79 3.28 ± 1.43 6.35 ± 7.40 0.208
  1. HLA human leucocyte antigen, ATG anti-thymocyte globulin, IL-2 interleukin-2, IQR interquartile range, eGFR estimated glomerular filtration rate, TNFSF13 Tumor necrosis factor superfamily 13, Gd-IgA1 Galactose deficient-IgA1